Intervet/Schering-Plough Animal Health Completes First Wave of launches of VectinR, an Antiparasitic Drug for Horses Formulated as a Tasty Cookie

BOXMEER (the Netherlands), September 29, 2009 – Intervet/Schering-Plough Animal Health today announces that it has completed the first wave of market introductions of VECTINR (ivermectin chewable tablets), a new broad spectrum horse dewormer that is formulated as a tasteful cookie. This innovative formulation combines high effectiveness in treating worm infections in the horse with easy administration.

Most deworming preparations for horses are available as an oral paste in a syringe. However, difficult syringe handling, often not optimized taste and the tendency of some horses to spit out part of the paste all constitute drawbacks of paste formulations, resulting in underdosing that can lead to development of parasite resistance. Moreover, a 2008 survey* has shown that paste administration difficulties contribute to frustration, anxiety and stress among owners when deworming their horses.

Such administration issues have now been addressed with VECTINR chewable cookies that are flavored with apple and molasses for increased acceptability. Most horses will take the cookies from the hand, but they also can be crumbled in the feed for further enhancement of acceptability. Field trials carried out in the USA and Europe for the licensing of VECTINR have shown acceptability of over 70 percent across all ages and across many breeds of horses as well as different husbandry conditions.

“With the introduction of VECTINR in the first markets we can offer another improved product that makes horse deworming an easy, effective and pleasant activity for both owners and horses”, said Hubert Trentesaux, Head Global Companion Animal at Intervet/Schering-Plough Animal Health.

VECTINR has recently been introduced in Germany, Hungary, the Netherlands and the United Kingdom, whereas market launch is ongoing in Sweden. More introductions are planned in European countries and elsewhere in the period to come.

VECTINR is a trademark owned by Intervet International B.V. This press release contains information on veterinary products based on international registration dossiers and may refer to products that are either not available in your country or are marketed under a different trade name. In addition, the safety and efficacy data for a specific product may be different depending on local regulations. For more information, read the product labeling that applies to your country or contact your local Intervet/Schering-Plough Animal Health representative.

### ENDS ###

* Equine Anthelminthic Resistance Project (November 2008), Veterinary Epidemiology and Economics Research Unit (VEERU), Reading University, Reading (United Kingdom)

About VECTINR VECTINR chewable tablets for horses are indicated for the treatment of nematode or arthropod infestations in horses due to large strongyles, small strongyles, lungworms, pinworms, ascarids, hairworms, large-mouth stomach worms, neck threadworms and stomach bots. The product contains a flavor and will be taken voluntarily by most horses. It can either be administered by hand, similar to a treat, or mixed with a small amount of feed. Each tablet contains 22.75 mg of ivermectin as an active substance.

About Intervet/Schering-Plough Animal Health Intervet/Schering-Plough Animal Health is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative Animal Health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. The company is based in Boxmeer, The Netherlands. For more information about Intervet/Schering-Plough Animal Health visit:  www.intervet.com

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com